| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT02414776 | Estrogen Receptor Positive Breast Cancer | Drug: hydroxychloroquine | Western Regional Medical Center | Phase 1 | 2014-07-01 | 2015-04-07 |
| NCT02874287 | Coronary Artery Disease | Drug: Hydroxychloroquine Sulfate Tablets|Drug: Placebo Tablets | First Affiliated Hospital Xi'an Jiaotong University | Phase 4 | 2016-08-01 | 2016-08-16 |
| NCT01760421 | Hashimoto Thyroiditis | Drug: Hydroxychloroquine | National Taiwan University Hospital | | 2011-10-01 | 2014-04-22 |
| NCT01687179 | Lymphangioleiomyomatosis | Drug: sirolimus and hydroxychloroquine | Brigham and Women's Hospital|National Heart, Lung, and Blood Institute (NHLBI) | Phase 1 | 2012-09-01 | 2016-08-11 |
| NCT02126683 | Hashimoto's Thyroiditis | Drug: Hydroxychloroquine | National Taiwan University Hospital | | 2014-04-01 | 2014-04-28 |
| NCT02351752 | Primary IgA Nephropathy | Drug: Hydroxychloroquine Sulfate | LLiu|Peking University First Hospital | Phase 4 | 2015-01-01 | 2015-12-15 |
| NCT01144169 | Renal Cell Carcinoma | Drug: Hydroxychloroquine (HC) | University of Pittsburgh|National Institutes of Health (NIH) | Phase 1 | 2010-10-01 | 2016-10-24 |
| NCT01273805 | Pancreatic Cancer | Drug: Hydroxychloroquine|Drug: Hydroxychloroquine | Dana-Farber Cancer Institute|Brigham and Women's Hospital|Massachusetts General Hospital | Phase 2 | 2010-12-01 | 2017-02-23 |
| NCT00632866 | Primary Sj枚gren's Syndrome | Drug: Hydroxychloroquine|Drug: Placebo | Assistance Publique - H么pitaux de Paris|Sanofi | Phase 3 | 2008-03-01 | 2012-07-01 |
| NCT00946790 | Immunosuppression|Rheumatism | Drug: Hydroxychloroquine Sulfate Tablets, 200 mg (Geneva Pharmaceutical, Inc.)|Drug: Hydroxychloroquine Sulfate Tablets, 200 mg, Plaquenil (Sanofi Winthrop) | Sandoz | Phase 1 | 1993-07-01 | 2009-07-24 |
| NCT02765594 | Primary IgA Nephropathy | Drug: Hydroxychloroquine Sulfate|Drug: Valsartan | Peking Union Medical College Hospital | Phase 4 | 2016-05-01 | 2016-05-04 |
| NCT01132118 | Rheumatoid Arthritis|Insulin Resistance | Drug: Hydroxychloroquine | Brigham and Women's Hospital|National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Phase 3 | 2010-06-01 | 2014-09-02 |
| NCT01266057 | Advanced Cancers | Drug: Hydroxychloroquine|Drug: Sirolimus|Drug: Vorinostat | M.D. Anderson Cancer Center | Phase 1 | 2011-04-01 | 2016-11-23 |
| NCT00771056 | B-Cell Chronic Lymphocytic Leukemia | Drug: Hydroxychloroquine | Northwell Health | Phase 2 | 2008-07-01 | 2016-08-18 |
| NCT01379573 | Congenital Heart Block|Neonatal Lupus|Autoantibody-Associated Heart Block | Drug: Hydroxychloroquine | New York University School of Medicine | Phase 2 | 2011-01-01 | 2016-09-21 |
| NCT02913157 | Multiple Sclerosis, Primary Progressive | Drug: Hydroxychloroquine | University of Calgary | Phase 2 | 2016-11-01 | 2017-01-27 |
| NCT01601028 | Autoimmune Diseases|Sjogren's Syndrome|Dry Eye | Drug: Hydroxychloroquine|Drug: Placebo | Seoul National University Hospital | Phase 3 | 2011-07-01 | 2013-10-16 |
| NCT00726596 | Prostate Cancer | Drug: hydroxychloroquine | Rutgers, The State University of New Jersey|Rutgers Cancer Institute of New Jersey|National Cancer Institute (NCI) | Phase 2 | 2008-08-01 | 2015-12-16 |
| NCT01128296 | Pancreatic Cancer | Drug: Hydroxychloroquine|Drug: Gemcitabine | University of Pittsburgh|National Institutes of Health (NIH) | Phase 1|Phase 2 | 2010-10-01 | 2015-01-13 |
| NCT02026232 | Type 2 Diabetes Mellitus | Drug: Hydroxychloroquine|Other: Hydroxychloroquine Placebo | Washington University School of Medicine | | 2012-03-01 | 2016-10-31 |
